Considering the increased CLL cells' sensitivity to CP and causing enhanced programmed cell death (PCD) or apoptosis, and suppressed malignant cell proliferation, our findings suggest a promising potential of using these NPs to achieve more efficient treatment of CLL patients. This evidence concerns the gene CP and B-cell chronic lymphocytic leukemia.